top of page
-
How does the VerAvanti SFE compare to current technologies like OCT and IVUS?The SFE provides forward-looking, true-color, real-time imaging. OCT and IVUS capture grayscale side-view frames that require interpretation. SFE makes visualization intuitive by showing what’s directly ahead, helping identify plaque rupture, calcified nodules, and true lumen pathways more easily and accurately.
-
Can the SFE see through blood inside live vessels?The commercial version requires saline flushing for clear images. A next-gen model using infrared wavelengths to see through blood is under development. It's a top R&D priority and expected to be a major leap forward once commercialized.
-
What specialties beyond cardiology are being explored?SFE is currently being tested across neurovascular, gastroenterology, ENT, pulmonology, urology, dental, and fluorescence-guided imaging. The initial commercial focus is intravascular, but the tech is being validated for full-body applications from head to toe.
-
Isn’t angioscopy an old technology? What makes this different?Yes, angioscopy existed in the 1990s but failed due to poor resolution, patient discomfort, and bulky probes. VerAvanti’s version solves these issues with sub-1mm fiber optics, MEMS-driven spiral scanning, no radiation, and clear imaging that works in real time.
-
Why is forward-looking imaging such a big deal for interventionists?It eliminates the need to mentally reconstruct anatomy from side-views and shadows. Instead of interpreting indirect signals, clinicians can directly see what lies ahead. This improves precision, reduces the risk of procedural errors, and speeds up decision-making.
-
Can the SFE see through blood inside live vessels?The commercial version requires saline flushing for clear images. A next-gen model using infrared wavelengths to see through blood is under development. It's a top R&D priority and expected to be a major leap forward once commercialized.
-
Can the SFE assist with stent planning or post-placement evaluation?Yes. The SFE enables clinicians to plan stent deployment, confirm positioning, and evaluate healing over time. It shifts imaging from static to dynamic, helping catch issues that might be missed using legacy systems.
-
How is VerAvanti handling the challenge of flushing and oxygenation during live procedures?Current saline flushing may limit use in some cases due to temporary blood displacement. However, ongoing R&D into an infrared-capable SFE aims to eliminate this need altogether, allowing visualization through blood without impacting downstream oxygenation.
-
What kind of data and software support does the SFE provide?While detailed analysis remains under wraps, the company is building software capabilities at the console level to interpret imaging, categorize findings, and potentially integrate with AI in future iterations to assist with diagnosis and navigation.
-
When will this be available for broader clinical use?The company is moving toward FDA clearance and has already invested over $40M in R&D, protected by 50+ patents. The intravascular market is the first beachhead, with expansion planned as regulatory milestones are met and manufacturing scales.
02
By The Numbers*
50+
Our technology is backed by over 50 patents, protecting and advancing exclusive imaging and endoscopic capabilities.
Patents For Advancing Imaging and Endoscopic Capabilities
10x
Our single-use design is crafted with the goal of reducing cross-contamination risks by up to 10 times the current rate, supporting safer procedures for patients.
We Aim To Reduce Cross-Contamination Risks
30%
Our technology is developed to help streamline complex procedures, with the potential to reduce operating time and improve patient throughput.
Possible Reduction In Procedure Time With Improved Efficiency
1
Our endoscope is designed to contribute to cost efficiency, with the possibility of just one additional procedure offering measurable ROI.
Procedure Aims To Cover The Entire Unit Investment
99.99%
Our device aims to achieve illumination efficiency far beyond standard CMOS cameras, working to provide clear and precise imaging for diagnostics.
Illumination Efficiency Potential vs. Traditonal CMOS Solutions
40%
Our advanced imaging technology aspires to support higher success rates with the goal of improving patient outcomes.
Aiming For Higher Success Rates In Complex Cases
* Source: JACC: Cardiovascular Interventions. "Chronic Total Occlusion Percutaneous Coronary Interventions: Evidence, Techniques, and Outcomes." Accessed at https://www.jacc.org/doi/full/10.1016/j.jcin.2009.02.008.
bottom of page